Literature DB >> 22861487

Dynamics and visualization of MCF7 adenocarcinoma cell death by aptamer-C1q-mediated membrane attack.

John R Stecker1, Alissa A Savage, John G Bruno, Dana M García, Joseph R Koke.   

Abstract

This study was designed to characterize binding of a DNA aptamer to breast cancer cells and to test whether that aptamer could be used to kill target cells in vitro as part of an aptamer-C1q protein conjugate by coupling to the classic complement cascade. A biotinylated DNA aptamer designated MUC1-5TR-1 was shown to decorate the plasma membranes of human breast adenocarcinoma (MCF7) cells via fluorescence confocal microscopy. Biotinylated aptamer binding successfully initiated the classical complement pathway leading to complement fixation on the target cells via a streptavidin-C1q conjugate as previously reported. Förster Resonance Energy Transfer (FRET) measurements demonstrated membrane depolarization upon aptamer binding, providing indirect evidence of membrane attack complex (MAC) formation as a result of aptamer binding. Transmission electron microscopy (TEM) and immunogold labeling confirmed that aptamer-mediated complement fixation results in MAC formation on the plasma membrane, leading to osmotic swelling and cell death. This approach may provide a much less toxic and more precisely targeted "antibody-like" treatment for cancers by coupling to the patient's innate immune system in much the same way as more expensive humanized monoclonal antibodies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22861487      PMCID: PMC3426207          DOI: 10.1089/nat.2012.0355

Source DB:  PubMed          Journal:  Nucleic Acid Ther        ISSN: 2159-3337            Impact factor:   5.486


  27 in total

1.  Neutralization of complement regulatory proteins augments lysis of breast carcinoma cells targeted with rhumAb anti-HER2.

Authors:  K Jurianz; S Maslak; H Garcia-Schüler; Z Fishelson; M Kirschfink
Journal:  Immunopharmacology       Date:  1999-05

Review 2.  Aptamers: an emerging class of molecules that rival antibodies in diagnostics.

Authors:  S D Jayasena
Journal:  Clin Chem       Date:  1999-09       Impact factor: 8.327

Review 3.  How much will Herceptin really cost?

Authors:  Ann Barrett; Tom Roques; Matthew Small; Richard D Smith
Journal:  BMJ       Date:  2006-11-25

4.  Nucleic acid aptamers for target validation and therapeutic applications.

Authors:  P Shannon Pendergrast; H Nicholas Marsh; Dilara Grate; Judith M Healy; Martin Stanton
Journal:  J Biomol Tech       Date:  2005-09

5.  Ultrastructural and physiological changes induced by atractylate in the canine myocardium.

Authors:  J R Koke; A L Shug; J D Folts; N Bittar
Journal:  Cytobios       Date:  1976

6.  Protection of the ischemic dog myocardium with carnitine.

Authors:  J D Folts; A L Shug; J R Koke; N Bittar
Journal:  Am J Cardiol       Date:  1978-06       Impact factor: 2.778

7.  Complement-mediated killing of microtumors in vitro.

Authors:  J Hakulinen; S Meri
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

8.  Soluble MUC1 secreted by human epithelial cancer cells mediates immune suppression by blocking T-cell activation.

Authors:  A K Chan; D C Lockhart; W von Bernstorff; R A Spanjaard; H G Joo; T J Eberlein; P S Goedegebuure
Journal:  Int J Cancer       Date:  1999-08-27       Impact factor: 7.396

9.  DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUC1-binding single-stranded DNA aptamers.

Authors:  C S M Ferreira; C S Matthews; S Missailidis
Journal:  Tumour Biol       Date:  2006-10-09

10.  DNA aptamers against the MUC1 tumour marker: design of aptamer-antibody sandwich ELISA for the early diagnosis of epithelial tumours.

Authors:  C S M Ferreira; K Papamichael; G Guilbault; T Schwarzacher; J Gariepy; S Missailidis
Journal:  Anal Bioanal Chem       Date:  2007-08-11       Impact factor: 4.142

View more
  9 in total

Review 1.  Aptamers as a novel tool for diagnostics and therapy.

Authors:  Onat Kadioglu; Anna Helena Malczyk; Henry Johannes Greten; Thomas Efferth
Journal:  Invest New Drugs       Date:  2015-02-01       Impact factor: 3.850

Review 2.  Recent Advances in Aptamers Targeting Immune System.

Authors:  Piao-Ping Hu
Journal:  Inflammation       Date:  2017-02       Impact factor: 4.092

Review 3.  Aptamers in the Therapeutics and Diagnostics Pipelines.

Authors:  Harleen Kaur; John G Bruno; Amit Kumar; Tarun Kumar Sharma
Journal:  Theranostics       Date:  2018-07-01       Impact factor: 11.556

Review 4.  Applications in Which Aptamers Are Needed or Wanted in Diagnostics and Therapeutics.

Authors:  John G Bruno
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-01

5.  A review of therapeutic aptamer conjugates with emphasis on new approaches.

Authors:  John G Bruno
Journal:  Pharmaceuticals (Basel)       Date:  2013-03-19

6.  Oligonucleotide aptamers: new tools for targeted cancer therapy.

Authors:  Hongguang Sun; Xun Zhu; Patrick Y Lu; Roberto R Rosato; Wen Tan; Youli Zu
Journal:  Mol Ther Nucleic Acids       Date:  2014-08-05       Impact factor: 10.183

7.  Supramolecular aptamer nano-constructs for receptor-mediated targeting and light-triggered release of chemotherapeutics into cancer cells.

Authors:  Deepak K Prusty; Volker Adam; Reza M Zadegan; Stephan Irsen; Michael Famulok
Journal:  Nat Commun       Date:  2018-02-07       Impact factor: 14.919

Review 8.  Potential Inherent Stimulation of the Innate Immune System by Nucleic Acid Aptamers and Possible Corrective Approaches.

Authors:  John G Bruno
Journal:  Pharmaceuticals (Basel)       Date:  2018-06-23

Review 9.  Predicting the Uncertain Future of Aptamer-Based Diagnostics and Therapeutics.

Authors:  John G Bruno
Journal:  Molecules       Date:  2015-04-16       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.